Hengrui Medicine: Remazolam Tosylate for Injection Obtained Clinical Trial Notice

2020-05-14
|
ChinaPharma

Hengrui Medicine announced that the company and its subsidiary Shanghai Hengrui Medicine Co., Ltd. recently received the "Clinical Trial Notice" approved by the State Drug Administration.


The drug name is Rimazoram Tosylate for Injection.


Rimazoram tosylate for injection is a short-acting GABAA receptor agonist. The indication for this approval is fiberoptic bronchoscopy for sedation.


RELATED ARTICLES

Memoray completes tens of millions of yuan in Series B financing
2020-11-18
|
PEVC , Medical care

JD Health and AstraZeneca start strategic cooperation
2020-11-18
|
Medical care , Pharmaceutical

Orthopedic AI company Changmugu closes Series A+ of RMB tens of mlns
2020-09-12
|
PEVC , Medical care

Lu Daopei Medical closes Series B+ exceeding RMB 100 mln
2020-09-11
|
PEVC , Medical care

JD.com reaches strategic cooperation with Tongrentang Health
2020-09-09
|
Medical care , PEVC

China's first COVID-19 vaccine produced by insect cells obtained clinical trial approval
2020-08-24
|
Pharmaceutical , Vaccine , Covid-19 , Biotech

Hengrui Medicine: HR18034 for injection will start clinical trials soon
2020-08-07
|
Medical care

China's first mRNA Covid-19 vaccine approved for clinical trials
2020-06-29
|
Covid-19 , Biotechnology

Bio-Thera: BAT1308 injection received notification of clinical trial
2020-05-28
|
Healthcare , Pharmaceutical

New drug application of Paimpril accepted by State Drug Administration
2020-05-26
|
Biopharmaceutical , Medical care
China SDG